Woburn, MA, December 19, 2007 - BioTrove, Inc. today announced the addition of Buzz Sztukowski to its executive management team as Senior Vice President and Chief Business Officer. Mr. Sztukowski brings to BioTrove more than 25 years' global experience in business and strategy development, as well as diagnostics product development and commercialization. His responsibilities at BioTrove will include managing and leading business operations development for the Molecular Diagnostics business, as well as spearheading continued growth for the OpenArray™ and RapidFire™ technology platforms.

"With his significant success developing health science businesses and technologies, and his experience positioning technology start-ups for profitable growth, Buzz will be a tremendous asset to BioTrove," said Albert A. Luderer, Ph.D., President and CEO, BioTrove. "At this exciting time for our company, Buzz will provide insight and perspective to guide the successful expansion of our business across life science, drug discovery and molecular diagnostics markets."

Formerly a Senior Vice President, Business Area Manager with bioMérieux of Lyon, France - a billion-euro global diagnostics company - Mr. Sztukowski was responsible for bioMérieux product development as well as global business and marketing strategies for the company's core business of Microbiology. Prior to bioMérieux, Mr. Sztukowski was President of Remel, Inc., a manufacturer and distributor of microbiology products. His experience also includes 13 years with Abbott Laboratories Diagnostic Division, where he held a series of positions with increasing responsibilities in sales and marketing management which contributed to market leadership in immunoassays.

"Our recent collaboration agreement with Applied Biosystems to commercialize our OpenArray™ platform for high-throughput genotyping applications, and our world wide agreement to co-market our RapidFire™ lead discovery system with Agilent, demonstrate the value of our technologies to researchers in both academia and industry - and we seek to expand both our presence and our impact on public health research," said Robert H. Ellis, Executive Chairman, BioTrove. "Buzz will be charged with continuing the growth of our OpenArray and RapidFire technology platforms, as well as our new venture into molecular diagnostics applications."

Mr. Sztukowski serves as a member of the Scientific Advisory Board of Expression Analysis, Inc., a full-service microarray genetics testing and analysis company. He received his BS, Life Science from Fontbonne University in St. Louis and his MBA from the University of Chicago.

About BioTrove, Inc.

BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world's ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove's products and services ensure that an industry committed to accuracy and speed can meet business goals.

RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.

The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.

For more information, please visit www.biotrove.com or contact:

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as should, planned, and expect, among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures. Practice of the patented 5' Nuclease Process requires a license from Applied Biosystems.

Applera, Applied Biosystems, and AB (Design) are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc.
Copyright © 2007. Applera Corporation. All rights reserved.

BioTrove, OpenArray, RapidFire, and the BioTrove logo are trademarks of BioTrove, Inc.
Copyright © 2007. BioTrove, Inc. All rights reserved.

Dr. Albert Luderer, President and CEO
BioTrove, Inc.
781-721-3648
info@biotrove.com

Arielle Bernstein
Makovsky + Company
212-508-9643
abernstein@makovsky.com